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Objectives: Many infrainguinal vein graft failures are due to progressive vein graft stenosis (VGS) from intimaI 
hyperplasia. Systemic factors have been implicated in the aetiology of intimal hyperplasia. Hyperhomocysteinaemia 
(HHCA) is established as an independent risk factor for coronary and peripheral rterial disease. The objective of this study 
was to examine the influence of HHCA and other serological factors upon the development ofVGS. 
Study design: Thirty-eight patients who had undergone infrainguinaI vein bypass were recruited to a case~control study 
from a graft surveillance program. Nineteen patients with documented VGS were matched against controls without 
stenosis for age, sex, length of time from surgery, diabetes, moking history and preoperative symptom score. All patients 
were recalled for Duplex ultrasound scans, venesection and carbon monoxide stimation which were performed in a blinded 
fashion. 
Results: Statistical analysis of all parameters evealed that plasma homocysteine was significantly elevated in patients with 
VGS (p < 0.3, Wilcoxon rank sum). 
Conclusions: These results suggest hat HHCA is a previously unidentified risk factor for VGS. Patients with HHCA are 
susceptible to VGS and preoperative investigation would allow identification of patients at risk. 
Key Words: Hyperhomocysteinaemia; Vein graft stenosis; Peripheral vascular disease. 
Introduction 
Autogenous vein is the most commonly used conduit 
for infrainguinal bypass grafting. Long term patency 
rates are superior to prosthetic materials but up to 30% 
of vein grafts fail in the first year. Early failures (less 
than i month) are often due to technical problems but 
intermediate failures in the first year are due to 
progressive vein graft stenosis (VGS) from intimal 
hyperplasia. The exact pathogenesis of intimal hyper- 
plasia is not fully understood although the mecha- 
nisms may well be similar to those of atherosclerosis. 
One systemic factor that has been shown to be an 
independent risk factor in atherosclerosis is hyper- 
homocysteinaemia (HHCA). ~-4 
The congenital disorder homocysteinuria, classi- 
cally due to a homozygous enzyme deficiency of 
cystathionine ~ synthase which irreversibly converts 
homocysteine to cystathionine, 5 is associated with 
very high plasma levels (> 100 ~tmol/1) of the thiol- 
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containing amino acid homocysteine. 6 The condition 
carries an increased risk of death from severe ather- 
omatous disease at an early age. Patients hetero- 
zygous for this genetic disorder show moderately 
raised levels of plasma homocysteine. A number of 
other congenital disorders of enzymes involved in 
homocysteine metabolism have also been identified as 
causing HHCA. 5 Vitamins B6, BI~ and folate are co- 
factors for homocysteine metabolism and acquired 
deficiencies may result in mild HHCA 2"5'7-9 and are 
much more common than congenital homocystei- 
nuria. HHCA is proposed as a potentially treatable 
risk factor for the development of atherosclerotic 
disease. 1°
Previous work in this unit has demonstrated that 
HHCA is an independent risk factor for accelerated 
peripheral vascular disease requiring vascular inter- 
vention. 11 It is postulated that homocysteine may 
cause endothelial cell injury via a direct toxic effect. 
Generation of free radicals 12 may initiate and/or 
promote intimal hyperplasia to produce VGS. The 
association between HHCA and VGS was examined 
by comparing plasma homocysteine levels in patients 
with and without VGS, utilising a retrospective case/ 
control methodology. 
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Patients and Methods 
From existing computerised atabases 19 patients 
were identified who had undergone infrainguinal 
bypass grafting (1988-1993) with autogenous vein for 
lower limb arterial disease and then progressed to a 
VGS between 6weeks and I year postoperatively. VGS 
was defined as angiographically determined lumen 
reduction of > 50% or with a persistent Duplex 
abnormality (minimum of two separate scans) with at 
least a doubling of velocities. Two patients were 
claudicants, 14 had critical limb ischaemia nd three 
had acute limb ischaemia. 13 Four patients were dia- 
betic. The graft stenoses were located at the proximal 
anastomosis n five patients, the mid-portion in four 
and the distal anastomosis in 10. Each patient was 
matched with a control from an ongoing graft surveil- 
lance programme who had undergone infrainguinal 
bypass grafting with vein at approximately the same 
time as the VGS patients but who had not developed 
a VGS, to form 19 matched pairs. Patients were 
matched for age (non-diabetic patients within 5 years, 
diabetic patients within 10 years), sex, the presence of 
diabetes (Insulin and Non-Insulin dependent sepa- 
rately matched), symptom severity score 13 (within two 
symptom score category divisions) and smoking 
history. 
All 38 patients were recalled for venesection and 
reassessment. Ankle brachial pressure indices (ABPI) 
at preoperative assessment and immediately post- 
operation were recorded. Preoperative run off scores 
after Rutherford et al. ~3 were noted. All of the control 
patients and any VGS patient with a patent, albeit 
stenosed graft, underwent Duplex scanning (HDI®, 
Advanced Technology Laboratories, Letchworth, 
Herts., U.K.). All of the control patients had patent 
non-stenosed grafts. Of the patients with a VGS, 11 
grafts were still patent and six grafts were blocked, 
two patients progressing to limb amputation. Inter- 
vention i.e. angioplasty or revision had occurred in 15 
patients. Carbon monoxide levels in expired air were 
estimated using a Bedfont Micro Smokerlyzer (Bed- 
font Scientific Ltd, Upchurch, Kent, U.K.). Venous 
blood (36ml) was taken from starved patients. A 
single whole blood sample was immediately stored in 
ice and spun to provide a plasma sample for freezing 
at -70°C within I h of venesection. This methodology 
has previously been demonstrated to be a reliable 
method of maintaining existing plasma levels of 
homocysteine at the time of venesection. A full blood 
count, clotting screen (including Protein C, Protein S, 
Antithrombin III, and Activated Protein C Resistance), 
plasma viscosity and serum fibrinogen levels were 
determined. Liver function tests and creatinine levels 
were measured and a full lipid profile assessed. 
Plasma samples were thawed in order to perform 
the homocysteine and antioxidant assays. Homo- 
cysteine levels were measured using a high perform- 
ance liquid chromatography technique. 14'15 Total 
plasma concentrations are measured by first liberating 
homocysteine from protein and mixed disulphides. 
Liberated thiols were then derivatised with a fluoro- 
genic reagent and 20 V1 of the sample measured by 
reverse phase high performance liquid chromatog- 
raphy. Initial studies on 107 healthy laboratory con- 
trols (75 male, 32 female, age range 21-63 years) found 
a mean plasma homocysteine concentration of 
9.7 ~mol/1 for men and 9.1 ~mol/1 for women. (upper 
95th centile values were 15.5 btmol/1 and 12.2 ~tmol/1 
respectively). Homocysteine concentrations above 
these values were taken as abnormal. 
Total antioxidant capacity (TAC) was determined 
using an enhanced chemiluminescent assay tech- 
nique. 16 This involved a steady production of free 
radicals which reacted with luminol to produce light 
emission which was measured by a lumimoneter. 
Addition of antioxidants caused a temporary quench- 
ing of free radical production, detectable as a reduc- 
tion in light emission. High levels of antioxidants 
caused a more prolonged reduction in light emission. 
The time (in seconds) until light emission recovers to 
10% of the initial output was taken as an index of 
TAC. 
Statistical analysis to determine the significance of 
observed ifferences between cases and controls was 
by the Wilcoxon Rank Sum Test. The significance of 
differences in all parameters between patients with 
HHCA and normals was determined by the Mann 
Whitney U-Test (MWU). 
Results 
Of 38 patients, 16 were women. Mean age at the time 
of vascular intervention was 70 years for cases and 69 
years for controls. Median age at recall was 72.5 years. 
Average length of time between vascular intervention 
and recall was 3 years. Of the 19 patients with VGS, six 
grafts had progressed to occlusion, two patients 
requiring limb amputation. Duplex examination con- 
firmed graft patency without VGS in controls and the 
presence of a VGS in those patients acting as cases 
with patent grafts. Carbon monoxide levels (parts per 
million - -  ppm) were similar in both cases 6.4ppm 
(1.64) (Mean + S.E.) and controls 5.6ppm (1.28) 
(Mean + s.E.)(Wilcoxon rank sum p = NS). Table 1 
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Table 1. Patient parameters cases and controls 
Cases 
(VGS patients) Controls 
Parameter n Value (range) n Value (range) 
Age (years) 19 70 (43) 19 69 (41) 
Preoperative ABPI 19 0.42 (0.34).64) 19 0.5 (0.18-0.7) 
Postoperative ABPI 19 0.83 (0.5-1) 19 0.9 (0.6-1) 
Preoperative Run Off* 19 1.9 19 2.1 
CO levels (ppm) 19 6.4 (1-24) 19 5.6 (1-18) 
APCR 14 2.73 (1.66-3.83) 12 2.68 (1.36-3.4) 
No. of APCR pts. 2 <2.2 2 <2.2 
Lipo (a) 10 0.17 (0.05-0.49) 10 0.3 (0.05-0.64) 
*"Run off" scoring as detailed by Rutherford et a113. 
APCR=Activated Protein C resistance; ABPI=Ankle Brachial 
Pressure Index; CO (ppm)=Carbon Monoxide (parts per million); 
Lipo (a)=Lipoprotein a. 
summarises the parameters of age, ABPI (pre and 
post-operation), runoff scores after Rutherford et al. 13 
and carbon monoxide levels. There were no differ- 
ences in ABPI (pre or postoperation) and run off scores 
between cases and controls. 
There was no significant difference between cases 
and controls in the following parameters; Full Blood 
Count (haemoglobi n, platelets, white blood cell 
count), viscosity. Thrombophil ia screen (International 
Normalised Ratio, Activated Partial Thromboplastin 
Time, Protein C, Protein S, Antithrombin III, plasmino- 
gen, Factor VII, Factor VIII and Factor III), Urea and 
Electrolytes, Liver Function Tests, Total Protein, Glob- 
ulins, and Lipid Profile (Total Cholesterol High 
Density Lipoprotein Cholesterol and Triacylglyceride) 
(Wilcoxon Rank Sum p = NS). The Activated Protein C 
Resistance (APCR) value for cases and controls, and 
the absolute numbers of patients in each group are 
given in Table 1. APCR could not be measured in 12 
patients on Warfarin, seven in the control group and 
five in the case group. It is clear that not only are there 
no differences between cases and controls in APCR 
values there is also no difference in the absolute 
numbers of patients with APCR; two in each group. It 
is of note however that the finding of a total of four 
patients with APCR in this study group (10%) is much 
higher than would be expected in a normal 
population. 
Serum and Red Blood Cell (RBC) Folate levels were 
not significantly different between cases and controls 
(Wilcoxon Rank Sum p = NS). The median plasma 
homocysteine l vel in the case group was 17.8 ~tmol/1 
(range 32) and in the control group 13.8 ~tmol/1 (range 
19.7) (Wilcoxon Rank Sum p < 0.03). Figs. 1 and 2 are 
scattergrams of the distributions of female and male 
patients. There is a trend to an increase in homo- 
cysteine levels that is not significant in the small 
female group of seven matched pairs (Wilcoxon rank 
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Fig. 1. Scattergram of plasma homocysteine levels: female patients 
(n = 14). Cases are patients with VGS while controls are free from 
VGS. Comparison of medians (range), cases: 17 (16), controls 15.5 
(13.5) with Wilcoxon Rank Sum; p = NS (--)  median. 
sum p = NS). In the male group with larger numbers, 
12 matched pairs, the difference between cases and 
controls is significant (Wilcoxon rank sum p < 0.005). 
Fig. 3 shows the combined male and female results 
with median values. The absolute value of homo- 
cysteine was not related to the degree of stenosis as 
assessed by Duplex ultrasound. The median plasma 
Lipoprotein (a) (Lipo (a)) level in the case group was 
0.17g/1 (range 0.44) and in the control group 0.3g/1 
(range 0.59) (Wilcoxon Rank Sum p < 0.02). The 
number of matched pairs with Lipo (a) concentrations 
that could be accurately measured was however only 
10 and the range in both cases and controls was wide 
(Table 1). TAC was not significantly different between 
cases (median, 540~tmol/1) and controls (median, 
514 ~tmol/1) (Wilcoxon Rank Sum p = NS). 
Homocysteine l vels greater than the 95th percentile 
for a normal healthy population were considered 
significantly raised. Nineteen patients had levels 
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Fig. 2. Scattergram of plasma homocysteine levels: male patients 
(n = 24). Cases are patients with VGS while controls are free from 
VGS. Comparison of medians (range), cases; 20 (32), controls 12 
(17.7) with Wil¢oxon Rank Sum; p < 0.005. (--)  median. 
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Fig. 3. Scattergram of plasma homocysteine levels: all patients 
(n = 38). Cases are patients with VGS while controls are free from 
VGS. Comparison ofmedians (range), cases 17.8 (32), controls 13.8 
(19.7) with Wilcoxon Rank Sum; p < 0.03. 
above the 95th centile. The incidence of HHCA was 
thus 50% in all patients tudied. All of the parameters 
were reanalysed comparing patients with normal 
plasma homocysteine l vels with patients with HHCA 
("normals'), without reference to the presence or 
absence of a VGS. This revealed significant differences 
in four parameters: erum folate, RBC folate, triacyl- 
glyceride and High Density Lipoprotein Cholesterol 
(HDL cholesterol) (Table 2). Patients with HHCA had 
low serum folates (3.1 ~g/1, HHCA patients; 4.5 ~g/1 
"normals')(MWU p < 0.01), low RBC folates 
(203 ~g/1, HHCA patients; 319 ~g/1 "normals') (MWU 
p < 0.001), high triacylglyceride (2.7 mmol/1, HHCA 
patients; 1.4mmol/1 "normals" ) (MWU p < 0.04), and 
low High Density Lipoprotein Cholesterol (1.1 mmol/ 
I, HHCA patients; 1.5mmol/1 "normals') (MWU 
p < 0.01). There was no difference in TAC between 
patients with HHCA (Median, 516 ~mol/1) and "nor- 
mals" (Median 524 ~mol/1)(MWU, p = NS). 
Discuss ion  
Autologous vein with its superior patency rates is 
Table 2. Differences in folate and lipid profiles between patients 
with HHCA and patients with normal plasma Homocysteine l vels 
Parameter 
HHCA Normals 
Median Median 
(interquartile range) (interquartile range) 
Serum Folate 
RBC Folate 
Triacylglyceride 
HDL Cholesterol 
3.1 ~g/1 (1.8-6.5) 
203 ~g/1 (160-300) 
2.7 mmol/1 (1.3-4.4) 
1.1 retool/1 (0.8-1.5) 
4.5 ~g/1 (4-6.6) 
319 gg/1 (260-520) 
1.4 retool/1 (1.1-2.1) 
1.5 mmol/1 (1.2-1.9) 
HHCA=hyperhomocysteinaemia; RBC=red blood cell; HDL=high 
density lipoprotein. 
now the conduit of choice for infrainguinal bypass 
grafting. Nevertheless the use of vein does not prevent 
a graft failure rate of up to 30%. Graft failure in the 
first few days may be due to technical error but failure 
within the first year is most likely to be due to 
progressive VGS secondary to intimal hyperplasia. 
The exact mechanism of intimal hyperplasia is unclear 
but some similarities with atherosclerotic change may 
exist. The aetiology of VGS is multifactorial and 
surgical technique, the intrinsic quality of the graft 
and systemic patient factors are all relevant. The 
systemic factors: plasma lipids, cholesterol, and homo- 
cysteine have all been implicated in the early presenta- 
tion of atherosclerosis and progression of diseaseY 
Some of the systemic factors such as plasma homo- 
cysteine that are known to play a role in athero- 
sclerosis may affect intimal hyperplasia and sub- 
sequent VGS. 
Total homocysteine was measured irectly from a 
fasting plasma sample without the need for methio- 
nine loading. The assay proved to be robust with good 
reproducibility and accuracy when prepared standard 
concentrations of homocysteine were studied. 15 
Raised levels of homocysteine have been reported in 
patients developing premature arterial disease in a 
number of sites. 4 The upper 95th percentile values 
established for healthy women and men were compat- 
ible with previous studies. 1'2"s'15 The reported inci- 
dence of HHCA in at risk groups ranges from 13 to 
38%. 1-3'7'1° The finding of HHCA in 50% (19/38) of all 
patients studied is thus higher than in previous 
reports. This may be because half of the patients 
selected to the study had a known VGS. The preva- 
lence of HHCA in the VGS group was 73% (14/19) 
and in the control group without VGS 26% (5/19). 
Both prevalences are higher than would be expected 
in a normal population, although these vary. 18 The 
high prevalence of HHCA in the case group and the 
raised levels with respect o controls suggests that 
HHCA may be important in the development of a 
VGS. 
The finding of lowered Lipo (a) levels in patients 
with VGS is contrary to previous reports, 19 but in this 
study only 10 matched pairs with complete data were 
available and interpretation of these results should be 
cautious. Patients with HHCA did not have levels of 
Lipo (a) significantly different from patients with 
normal homocysteine levels. Previous reports on 
patients with both PTFE and vein grafts have found 
mean Lipo (a) concentrations in controls 30 times 
lower than in this study. 19 The reason for differences in 
Lipo (a) levels in this study is unclear but may be an 
effect of sample size and sampling error. 
Analysis of all parameters with respect o patients 
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with a normal evel of homocysteine and patients with 
HHCA, disregarding the presence or absence of a 
VGS, reveals abnormalities of folate and lipid metabo- 
lism. Patients with HHCA have low levels of both 
serum folate and RBC folate. This has been previously 
described. 8"2° It supports the theory that in some 
susceptible patients deficiency of serum folate can 
lead to HHCA via a reduction in the availability of 
methyl groups for remethylation of homocysteine to
methionine. The absence of a macrocytic anaemia in 
any of the patients studied would suggest normal 
levels of B6 of B12 although these were not measured 
directly. High levels of triacylglyceride and low levels 
of HDL cholesterol have been demonstrated to be risk 
factors for the development of atherosclerosis. The 
finding of deranged lipid metabolism in this study 
supports an association between the proatherogenic 
state induced by high triacylglycerides and low HDL 
cholesterol and HHCA. The exact mechanism of this 
effect is unclear but the idea of lipid peroxidation by 
homocysteine is an attractive one. Blom et al. could not 
demonstrate an in vivo relationship between lipid 
peroxidation and HHCA. 21 
Homocysteine has previously been shown to be 
associated with the development and progression of 
lower limb arterial disease. 1 This study found that 
HHCA is a risk factor for VGS. Although the develop- 
ment of atherosclerotic lesions and intimal hyper- 
plasia are different processes, there are pathophysio- 
17.22 logical similarities. ' HHCA endothelial cell injury 
may underlie both processes. The pathogenesis of 
homocysteine's adverse effects are unknown and a 
direct causal relationship between HHCA and athero- 
sclerosis has not been conclusively demonstrated in 
vivo. Stakebaum et al. reported that cultured endothe- 
lial cells were injured by hydrogen peroxide generated 
by a copper catalysed oxidation of homocysteine. 23 
There was no association between HHCA and TAC 
and this would support the findings of Blom et a lY  
but the association between disordered lipid metabo- 
lism (high levels of triacylglyceride and low HDL 
cholesterol) and HHCA suggest hat homocysteine 
has some effect on lipid levels. Stamler et al. postu- 
lated that homocysteine may react in vivo with nitric 
oxide to produce a compound with vasodilatory and 
antithrombotic properties. 24It maybe that it is only in 
the absence of nitric oxide resulting from endothelial 
cell injury that homocysteine produces its adverse 
effects and that this may explain the conflicting in vivo 
and in vitro results. In summary, the pathogenesis of
homocysteine's apparent adverse effects on arterial 
disease remain unclear. 
In conclusion, this study confirms the association 
between HHCA and peripheral vascular disease. 
HHCA was found to be a risk factor for the develop- 
ment of VGS. The pathogenesis of homocysteine's 
adverse effects on arterial disease remains unclear. 
Although a direct causal ink between arterial injury 
and elevated levels of homocysteine appears likely 
this has not been conclusively demonstrated in vivo. 
Further work is necessary to explore the relationship 
between HHCA and disordered folate and lipid 
metabolism. If the mechanism of HHCA mediated 
atherosclerosis can be determined the clinical response 
to biochemical correction of this disorder may be 
better understood. 
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